What question did this study set out to answer?

This analysis aims to evaluate the efficacy and safety of vutrisiran in East Asian patients with hereditary transthyretin-mediated amyloidosis.

March 7, 2026Open Access

Efficacy and Safety of Vutrisiran in Patients with Hereditary Transthyretin-mediated Amyloidosis with Polyneuropathy: Analysis of the East Asian Subpopulation from HELIOS-A

Key Points

This analysis aims to evaluate the efficacy and safety of vutrisiran in East Asian patients with hereditary transthyretin-mediated amyloidosis.
Conducted a post hoc analysis of the HELIOS-A trial data
Focused on the East Asian subpopulation
Compared outcomes with the overall study population
Vutrisiran showed similar outcomes in East Asian patients as in the overall population
Indicated effective treatment with good tolerance

Abstract

Although the number of East Asian patients in HELIOS-A was small, this post hoc analysis showed similar outcomes to those in the overall study populations, indicating that vutrisiran is effective and well tolerated in East Asian patients.

Bookmark

View Full Paper

Cite This Study

Oh et al. (Wed,) studied this question.

synapsesocial.com/papers/69abc0925af8044f7a4e94be https://doi.org/https://doi.org/10.1007/s40120-026-00899-y

Bookmark

View Full Paper